Citations

Showing 10 of 108119 citations.

A Comprehensive Review of Cerebral Oximetry in Cardiac Surgery
Moore, Christina , Aljure, Oscar , Aljure, Oscar D , Moore, Christina C , Yu, Soojie

Mayo Clinic

No container title available | December 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163865084.42939677/v1 Get It

Background: Patients who undergo cardiac surgery are at increased risk of stroke, postoperative cognitive decline, and delirium. These neurocognitive complications have led to increased costs, intensive care unit stays, morbidity, and mortality. As a result, there is a significant push to mitigate any neurological complications in cardiac surgery patients. Near-infrared spectroscopy to measure regional cerebral oxygen saturations has gained consideration due to its non-invasive, user-friendly, and relatively inexpensive nature. Aim of Study: To provide a comprehensive summary of cerebral oximetry in cardiac surgery. The review interrogates multiple systematic reviews assessing different outcomes in cardiac surgery to assess if cerebral oximetry is effective. Further, the review analyzes all available interventions for an acute desaturation to determine the efficacy of individual interventions. Methods: A narrative review of randomized controlled trials, observational studies, and systematic reviews with metanalyses were performed through August 2021. Results: There is significant heterogeneity amongst studies regarding the definition of a clinically significant cerebral desaturation. In addition, the assessment of neurocognitive outcomes has large variability, making metanalysis challenging. To date, cerebral oximetry use during cardiac surgery has not been associated with improvements in neurocognitive outcomes, morbidity, or mortality. The evidence to support particular interventions for an acute desaturation is equivocal. Conclusions: Future research is needed to quantify a clinically significant cerebral desaturation and to determine which interventions for an acute desaturation effectively improve clinical outcomes.
Catheter Ablation Versus Medical Therapy for Atrial Fibrillation - Penny wise Pound Foolish !
Kowlgi, Gurukripa N. , Deshmukh, Abhishek , Kowlgi, Narayan G

Mayo Clinic

No container title available | December 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163864894.46936919/v1 Get It

Catheter ablation for atrial fibrillation has emerged as a main stay for management of atrial fibrillation. It has been shown to be clinically effective and cost effective in multiple trials .
Imaging features of cartilaginous tumors of the head and neck
Wangaryattawanich, Pattana , Agarwal, Mohit , Rath, Tanya, Rath, Tanya J.

Mayo Clinic

Journal of Clinical Imaging Science | December 4, 2021 | Volume: 11 | Issue: No issue available | Pages: 66

10.25259/jcis_186_2021 | PMID 34992942 Get It

There is a wide spectrum of head and neck cartilaginous lesions which include both neoplastic and nonneoplastic processes. Cartilaginous tumors of the head and neck are uncommon, posing a diagnostic challenge. Benign cartilaginous tumors that may occur in the head and neck include chondroma, chondroblastoma, chondromyxoid fibroma, osteochondroma, and synovial chondromatosis. Chondromesenchymal hamartoma is a rare non-neoplastic cartilaginous lesion that is included for the 1first time in the new WHO classification and radiologically can mimic a tumor. Malignant cartilaginous tumors include chondrosarcoma and chondroid variant of chordoma. Characteristic tumor locations, internal chondroid matrix calcification, and typical T2 hyperintense signal secondary to high-water content within the extracellular matrix of the hyaline cartilage are useful imaging features that narrow the differential diagnosis and help in diagnosing these diseases. This article presents a narrative review of the anatomy of the head and neck cartilaginous structures, discusses the current knowledge and imaging spectrum of benign and malignant cartilaginous tumors and tumor-like lesions of the head and neck.
Health‐related quality of life is dynamic in alcoholic hepatitis and responds to improvement in liver disease and reduced alcohol consumption
Madathanapalli, Abhishek, Tang, Qing , Lammert, Craig , Shah, Vijay H. , Chalasani, Naga , Desai, Archita P. , Desai, Archita P , Samala, Niharika , Sanyal, Arun J.

Mayo Clinic

Alcoholism: Clinical and Experimental Research | December 4, 2021 | Volume: 46 | Issue: 2 | Pages: 252-261

10.1111/acer.14756 | PMID 34862610 Get It

AbstractBackgroundThe impact of alcoholic hepatitis (AH) on health‐related quality of life (HRQOL) remains inadequately described. We aimed to characterize HRQOL in AH and heavy drinkers (HD), and its associations with clinical variables and outcomes.MethodsThis is a post hoc analysis of participants in the Translational Research and Evolving Alcoholic Hepatitis Treatment 001 study (NCT02172898). HRQOL was measured using Short Form Health Survey (SF‐36). Mean SF‐36 scores were compared in AH and HD with two‐sample t‐tests. Associations among clinical characteristics, 30‐day mortality, and SF‐36 mental and physical component scores (MC, PC) were investigated with generalized linear and logistic multivariate regression models. Trends of MC and PC scores were analyzed using one‐way ANOVA.ResultsParticipants with AH (n = 258) and HD (n = 181) were similar demographically. AH cases had a mean Model for End‐stage Liver Disease (MELD) score of 23 (7). AH cases had lower PC scores [37 (10) vs. 48 (11), p < 0.001] but higher MC scores [37 (13) vs. 32 (13), p < 0.001]. MC scores were independently associated with age, male gender, and daily alcohol consumption; PC scores were independently associated with age, BMI, alanine aminotransferase concentration, alkaline phosphatase concentration, white blood cell counts, and the presence of ascites. With each 5‐point decrease in the baseline PC score, the adjusted odds of dying within 30 days increased by 26.7% (95% CI 1% to 46%). Over time, HRQOL in AH improved (day 0 to day 180 delta PC score: 4.5 ± 1.7, p = 0.008; delta MC score: 9.8 ± 2.0, p < 0.001). Participants with a MELD score <15 by day 180 had greater increases in PC scores than those with MELD score ≥15 (delta PC score 7.1 ± 1.8 vs. −0.7 ± 2.3, p = 0.009), while those abstinent by day 180 had greater increases in MC scores than those who were not abstinent (delta MC score 9.1 ± 1.8 vs. 2.8 ± 2.4, p = 0.044).ConclusionsHRQOL is poor in AH and HD in a domain‐specific pattern. Independent of MELD score, lower baseline HRQOL is associated with higher 30‐day mortality. Over time, HRQOL improves with greater gains seen in individuals with improved MELD scores and those who were abstinent.
Implications of Cannabidiol in Pharmacogenomic-Based Drug Interactions with CYP2C19 Substrates
Engeleit, Anastasia , Crosby, Sheena , Schuh, Michael J.

Mayo Clinic

The Senior Care Pharmacist | December 4, 2021 | Volume: 36 | Issue: 12 | Pages: 674-680

10.4140/tcp.n.2021.674 | PMID 34861907 Get It

This is a patient case exploring the importance of evaluating herbal and dietary supplements and how they may impact drug-drug and drug-gene implications based on pharmacogenomics test results. Even though herbal supplements are considered natural by many patients, which is often the reason for starting them, herbal supplements may still be metabolized by the same pathways as other medications, potentially contributing to drug-drug, drug-herb, and drug-gene interactions, and therefore, potentially impacting a patient’s response to medications.
Primary hyperoxaluria type 1: novel therapies at a glance
Bacchetta, Justine , Lieske, John C.

Mayo Clinic

Clinical Kidney Journal | December 3, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: i17-i22

10.1093/ckj/sfab245 | PMID 35592618 Get It

ABSTRACT Primary hyperoxaluria type 1 (PH1) is a rare and severe autosomal recessive disease of oxalate metabolism, resulting from a mutation in the AGXT gene that encodes the hepatic peroxisomal enzyme alanine–glyoxylate aminotransferase (AGT). Until recently, treatment of PH1 was supportive, consisting of intensive hyperhydration, use of crystallization inhibitors (citrate and neutral phosphorus), in a subset of responsive PH1 patients’ pharmacologic doses of vitamin B6 (pyridoxine), and kidney and liver transplantation when patients progressed to kidney failure. Treatment approaches have been similar for PH2 caused by mutations in hepatic glyoxylate reductase/hydroxypyruvate reductase (GR/HPR), although pyridoxine does not have any benefit in this group. PH3 is caused by mutations of mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA1) and was the most recently described. Kidney failure appears less common in PH3, although kidney stones occur as frequently as in PH1 and PH2. Oxalate metabolism in the liver is complex. Novel therapies based on RNA interference (RNAi) have recently emerged to modulate these pathways, designed to deplete substrate for enzymes upstream and decrease/avoid oxalate production. Two hepatic enzymes have been targeted to date in PH: glycolate oxidase (GO) with lumasiran and lactate dehydrogenase A (LDH-A) with nedosiran. Lumasiran was approved for the treatment of PH1 in 2020 by both the European Medicines Agency and the Food and Drug Administration, whilst clinical trials with nedosiran are ongoing. Results with the two RNAi therapies demonstrate a significant reduction of urinary oxalate excretion in PH1 patients, but long-term data on efficacy (preservation of kidney function, decreased stone events) and safety remain to be established. Nevertheless, the hepatically targeted RNAi approach represents a potential ‘game changer’ in the field of PH1, bringing hope to families and patients that they may be able to avoid liver and/or kidney transplantation in the future and suffer fewer stone events, perhaps with less strict therapeutic regimens. Pharmacological compounds directly inhibiting GO or LDH are also under development and could be of special interest in developing countries where RNAi therapies may not be readily available in the near future. Approaches to manipulate the intestinal microbiome with a goal to increase oxalate degradation or to stimulate secretion of oxalate into the intestine from plasma are also under development. Overall, we appear to be entering a new phase of PH treatment, with an array of promising approaches emerging that will need optimization and evaluation to establish long-term efficacy and safety.
Time to Flexible Sigmoidoscopy or Colonoscopy in Patients Admitted With Ulcerative Colitis Has Decreased From 2012 to 2018
Bali, Aman S. , Picco, Michael F., Bali, Aman , Hashash, Jana G. , Farraye, Francis A. , Kröner, Paul T.

Mayo Clinic

Crohn's & Colitis 360 | December 3, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/crocol/otab080 | PMID 36777265 Get It

Abstract Background Early endoscopic evaluation of patients with ulcerative colitis (UC) enables assessment of disease activity and accurate diagnosis based on exclusion of other similarly presenting conditions including infections. Early endoscopy is also associated with improved outcomes of patients with active UC. The aim of this study was determining temporal trends in endoscopy in patients with UC over a 7-year period from 2012 to 2018. Methods Retrospective cohort study using the National Inpatient Sample 2012–2018. Patients admitted with ICD-9–10 principal codes for UC were included. Early endoscopy using flexible sigmoidoscopy (FS) or colonoscopy was defined as performed within 48 hours of admission. The primary outcome was trends in endoscopy timing. Secondary outcomes were inpatient morbidity, mortality, length of stay (LOS), and hospitalization charges/costs comparing patients undergoing early vs nonearly endoscopy using multivariable regression. Results Of 222 460 patients hospitalized with UC, 5900 (2.7%) underwent FS and 43 345 (19.5%) underwent colonoscopy. The rate of endoscopy increased from 3.9% (2.3% early) to 39.3% (23.3% early) from 2012 to 2018 (P &lt; .01). Early endoscopy was associated with statistically significant decreased mortality, shock, multiorgan failure, and intensive care unit odds, as well as decreased resource utilization and LOS. Conclusions In patients hospitalized with UC, early endoscopy rates were low but performed more frequently from 2012 to 2018. This may reflect increasing awareness of improved outcomes from earlier disease staging and/or diagnosis. Early endoscopy was associated with decreased resource utilization and hospitalization-related outcomes, highlighting the importance of early endoscopy in patients admitted with UC.
Endoscopic sleeve gastroplasty and postprocedural nutritional deficiencies: results from a single center exploratory study
Ghoz, Hassan, Bryant, Mikel, Fritz, Haley, Brown, Lauren, Ames, Gretchen, Ghazanfari, Lisa, Lynch, Scott A., Osborne, Tina, Gómez, Victoria, Ghoz, Hassan, Bryant, Mikel, Fritz, Haley, Brown, Lauren, Ames, Gretchen, Ghazanfari, Lisa, Lynch, Scott A., Osborne, Tina, Gómez, Victoria

Mayo Clinic

European Journal of Gastroenterology & Hepatology | December 3, 2021 | Volume: 33 | Issue: 1S | Pages: e1039-e1041

10.1097/meg.0000000000002316 | PMID 35048661 Get It

Nutritional deficiencies following endoscopic sleeve gastroplasty (ESG) are unknown. We retrospectively studied nutritional deficiencies in 20 patients who underwent ESG at our institution. No subjects had preprocedural anemia, whereas 22.2% (N = 2/9) developed anemia at 12 months. Vitamin D deficiency developed in one subject post-ESG. Vitamin A, E, C and magnesium deficiencies developed in 8.3% (N = 1/12), 18.2% (N = 2/11), 14.3% (N = 1/7) and 10% (N = 1/10) of subjects, respectively, at 12 months. Vitamin B12 and B6 deficiencies were detected in 12.5 and 14.3% of the subjects at baseline, however, resolved at 12 months. There were no pre- or postprocedural deficiencies in zinc, selenium, copper, folate, thiamine, phosphorus or calcium. In this study, nutritional deficiencies were observed in a very small subset of patients at various time points after ESG.
MR-guided Cryoablation for the Treatment of Symptomatic Pedal Vascular Malformations
Koepsel, Erica M. Knavel , Bendel, Emily C. , Augustine, Matthew , Tollefson, Megha M. , Gorny, Krzysztof R. , Lu, Aiming , Favazza, Christopher , Woodrum, David A. , Thompson, Scott M.

Mayo Clinic

Journal of Vascular Anomalies | December 3, 2021 | Volume: 2 | Issue: 4 | Pages: e029

10.1097/jova.0000000000000029 Get It

Objective: Vascular malformations are benign vascular anomalies characterized by abnormally developed arterial, venous, and lymphatic structures, which are often symptomatic. Historical and current treatment techniques include intravascular embolization/sclerosis and surgical resection. While these techniques have proven to be successful at managing and treating these types of lesions, these techniques are not without risk, especially in the small spaces of the hands and feet. Cryoablation for the treatment of low-flow vascular malformations is a new and evolving technique. We present five cases of symptomatic pedal vascular malformations treated with MR guided cryoablation, which provides encouraging safety and feasibility results for these difficult to treat lesions. Methods: A retrospective review of patients who had undergone MR-guided cryoablation of their pedal vascular malformations between January 2016 and January 2020 was performed. Results: Five cryoablations were completed without immediate complication. All patients reported markedly decreased pain corresponding to the treated area and improvement in their ability to return to a more active lifestyle. Two patients experienced mild transient numbness which resolved by 2–3 months and one patient experienced a transient motor and sensory neuropathy which resolved by 6 months. Conclusion: We present five cases of successful MR-guided cryoablation of symptomatic pedal venous malformations. Many of the patients included in this review failed conservative and other interventional/surgical treatments. The treatment options for this patient cohort can be limited given small space within the plantar aspect of the foot. Cryoablation of these lesions can be performed safely especially under continuous MRI monitoring. Level of Evidence: Case series (Level 4)
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
Hamadani, Mehdi , Ngoya, Maud , Sureda, Anna , Bashir, Qaiser , Litovich, Carlos, Finel, Hervé , Zain, Jasmine , Cashen, Amanda F. , Blaise, Didier , Pastano, Rocco , Khimani, Farhad , Schmitz, Norbert , Glaß, Bertram , Kharfan‐Dabaja, Mohamed A. , Sauter, Craig S. , Montoto, Silvia , Herrera, Alex F. , Dreger, Peter , Boumendil, Ariane , Blaise, Didier , Shadman, Mazyar , Pastano, Rocco , Arat, Mutlu , Dietrich, Sascha , Kharfan-Dabaja, Mohamed A , Montoto, Silvia , Herrera, Alex F , Hamadani, Mehdi , Chen, Yue , Boumendil, Ariane , Castagna, Luca , Shadman, Mazyar , Corradini, Paolo , Kwon, Mi

Mayo Clinic

Blood Advances | December 3, 2021 | Volume: 6 | Issue: 3 | Pages: 920-930

10.1182/bloodadvances.2021005899 | PMID 34861680 Get It

Abstract Mature T-cell lymphomas constitute the most common indication for allogeneic hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas relative to commonly used donor sources are not available. Included in this registry study were adult patients who had undergone allo-HCT for anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) between 2008 and 2018. Hematopoietic cell transplantation (HCT) platforms compared were posttransplant cyclophosphamide-based haploidentical (haplo-)HCT, matched sibling donor (MSD) HCT, matched unrelated donor HCT with in vivo T-cell depletion (MUD TCD+), and matched unrelated donor HCT without in vivo T-cell depletion (MUD TCD−). Coprimary end points were overall survival (OS) and progression-free survival (PFS); secondary end points included nonrelapse mortality (NRM), and relapse/progression incidence (RI). A total of 1942 patients were eligible (237 haplo-HCT; 911 MSD; 468 MUD TCD+; 326 MUD TCD−). Cohorts were comparable for baseline characteristics with the exception of higher proportions of patients with decreased performance status (PS) and marrow graft recipients in the haplo-HCT group. Using univariate and multivariate comparisons, OS, PFS, RI, and NRM were not significantly different among the haplo-HCT, MSD, MUD TCD+, and MUD TCD− cohorts, with 3-year OS and PFS of 60%, 63%, 59%, and 64%, respectively, and 50%, 50%, 48%, and 52%, respectively. Significant predictors of inferior OS and PFS on multivariate analysis were active disease status at HCT and decreased PS. AITL was associated with significantly reduced relapse risk and better PFS compared with PTCL-NOS. Allo-HCT can provide durable PFS in patients with mature T-cell lymphoma (TCL). Outcomes of haplo-HCT were comparable to those of matched donor allo-HCT.